Navigation Links
Breast cancer patients prefer silicone over saline implants after mastectomy
Date:11/8/2010

A new study has found that women who receive silicone implants after a double mastectomy are more satisfied with their breasts than women who receive saline implants. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help physicians and breast cancer survivors as they together make decisions related to postmastectomy reconstructive surgery.

Women who have one or both of their breasts removed as a treatment for breast cancer may wish to undergo breast reconstructive surgery with implants. Such postmastectomy implants may be filled with either saline (salt water) or silicone gel, and while both types have been approved by the US Food and Drug Administration, the safety and effectiveness of breast implants remain under close scrutiny. In addition to safety and efficacy, patient satisfaction and quality of life are also important considerations when comparing implant types. To this end, Colleen McCarthy, MD, of Memorial Sloan-Kettering Cancer Center in New York City led a team that surveyed 672 women who had undergone postmastectomy reconstructive surgery with implants at one of three centers in North America.

A total of 472 patients in the study completed questionnaires. In 176 women, silicone implants were placed; in 306, saline implants were used. The investigators found that patients with silicone implants were more satisfied with their reconstructed breasts than patients with saline implants. Receiving radiation therapy after a mastectomy had a significantly negative effect on breast satisfaction in both silicone and saline implant recipients. In addition, for women who received either silicone or saline implants, satisfaction diminished over time.

"We now know that women who elect to proceed with the placement of a silicone implant report higher satisfaction with their reconstructed breasts than those who choose saline implants," said Dr. McCarthy. "It also appears that patient satisfaction with postmastectomy implant-based reconstruction is generally high and that individual treatment variablessuch as implant typeexplain only a relatively small amount of the variance. Patient counseling should reflect these realities in order to reassure patients that high satisfaction may be obtained with both saline and silicone implants," she added.


'/>"/>

Contact: Jennifer Beal
healthnews@wiley.com
44-012-437-70633
Wiley-Blackwell
Source:Eurekalert

Related biology news :

1. Even the sickest babies benefit from breast-feeding
2. Consuming vegetables linked to decreased breast cancer risk in African-American women
3. Clue to unusual drug-resistant breast cancers found
4. Breast density linked to increased risk of subsequent breast cancer
5. Black mothers cite lack of desire as top reasons for not breastfeeding
6. Breast cancer diagnostic delay depends more on race than insurance
7. Decreased survival for Puerto Rican women with triple-negative breast cancer subtype
8. Racial differences in breast cancer treatment persist despite similar economics
9. Marshall University researchers awarded more than $1 million for breast cancer studies
10. Fat stem cells safe for breast reconstruction when cancer is dormant, says Pitt team
11. Alcohol consumption after breast cancer diagnosis may increase recurrence risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
(Date:11/29/2016)... France , November 29, 2016 Nearly one ... Continue Reading ... ... is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This ... products engineered to radically streamline culture processes, minimize processing time, significantly decrease ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
(Date:12/7/2016)... 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces ... at the Company,s Annual and Special Meeting. ... place on Thursday, December 15, 2016 at Mount ... EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta ... meeting and management information circular, containing the matters to be ...
Breaking Biology Technology: